Edit Remák

427 total citations
31 papers, 336 citations indexed

About

Edit Remák is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Edit Remák has authored 31 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Economics and Econometrics, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Edit Remák's work include Renal cell carcinoma treatment (10 papers), Economic and Financial Impacts of Cancer (9 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Edit Remák is often cited by papers focused on Renal cell carcinoma treatment (10 papers), Economic and Financial Impacts of Cancer (9 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Edit Remák collaborates with scholars based in United Kingdom, United States and France. Edit Remák's co-authors include L. Brazil, Claudie Charbonneau, Sylvie Négrier, Robert J. Motzer, Sindy T. Kim, Martin Price, Michael Trimble, Caroline Selai, John Hutton and Robert A. Figlin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and British Journal of Cancer.

In The Last Decade

Edit Remák

29 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Edit Remák United Kingdom 10 143 132 94 61 53 31 336
Lisel Koepl United States 11 48 0.3× 87 0.7× 156 1.7× 58 1.0× 33 0.6× 12 325
Per-Olof Thuresson Switzerland 8 97 0.7× 98 0.7× 85 0.9× 45 0.7× 44 0.8× 22 390
Anna Plym Sweden 12 36 0.3× 141 1.1× 124 1.3× 53 0.9× 23 0.4× 28 330
Aviva G. Asnis-Alibozek United States 5 52 0.4× 131 1.0× 170 1.8× 68 1.1× 23 0.4× 7 489
Timo Purmonen Finland 12 96 0.7× 74 0.6× 62 0.7× 33 0.5× 18 0.3× 24 321
S.M. Babineaux United States 6 40 0.3× 109 0.8× 85 0.9× 20 0.3× 43 0.8× 11 397
K.R. Loughlin United States 6 35 0.2× 276 2.1× 93 1.0× 30 0.5× 107 2.0× 6 407
Christine Langenaeken Belgium 7 71 0.5× 69 0.5× 112 1.2× 14 0.2× 37 0.7× 12 351
V. Geyer Germany 6 49 0.3× 55 0.4× 130 1.4× 19 0.3× 108 2.0× 10 412
P. Stattin Sweden 5 27 0.2× 271 2.1× 133 1.4× 42 0.7× 61 1.2× 6 369

Countries citing papers authored by Edit Remák

Since Specialization
Citations

This map shows the geographic impact of Edit Remák's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edit Remák with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edit Remák more than expected).

Fields of papers citing papers by Edit Remák

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edit Remák. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edit Remák. The network helps show where Edit Remák may publish in the future.

Co-authorship network of co-authors of Edit Remák

This figure shows the co-authorship network connecting the top 25 collaborators of Edit Remák. A scholar is included among the top collaborators of Edit Remák based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edit Remák. Edit Remák is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Muszbek, N., et al.. (2023). Cost–utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma. Journal of Comparative Effectiveness Research. 12(7). CER–CER.
2.
Torres, Antoni, Àlex Soriano, Edit Remák, et al.. (2022). Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System. SHILAP Revista de lepidopterología. 3 indexed citations
3.
Muszbek, N., et al.. (2021). Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert Review of Pharmacoeconomics & Outcomes Research. 22(1). 147–154. 2 indexed citations
4.
5.
Muszbek, N., et al.. (2020). Cost–Utility Analysis of Selective Internal Radiation Therapy with Y-90 Resin Microspheres in Hepatocellular Carcinoma. Future Oncology. 17(9). 1055–1068. 9 indexed citations
6.
Muszbek, N., et al.. (2019). PCN78 CHANGES IN HEALTH STATE COSTS IN HEPATOCELLULAR CARCINOMA (HCC). Value in Health. 22. S451–S451. 1 indexed citations
7.
8.
Torres, Antoni, Matteo Bassetti, Tobias Welte, et al.. (2019). Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. Journal of Medical Economics. 23(2). 148–155. 2 indexed citations
9.
Remák, Edit, et al.. (2019). <p>A cost-consequence analysis of parecoxib and opioids vs opioids alone for postoperative pain: Chinese perspective</p>. ClinicoEconomics and Outcomes Research. Volume 11. 169–177. 8 indexed citations
10.
Soriano, Àlex, Edit Remák, Michal Kantecki, et al.. (2018). PIN63 - A COST-MINIMIZATION MODEL TO EVALUATE THE IMPACT OF CEFTAROLINE FOSAMIL FOR THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS IN HOSPITALIZED ADULTS IN SPAIN. Value in Health. 21. S231–S231. 3 indexed citations
11.
Heras, B. Bermejo De Las, Juan de la Haba-Rodríguez, Jesús García Mata, et al.. (2018). The economic burden of metastatic breast cancer in Spain. European Journal of Hospital Pharmacy. 27(1). 19–24. 16 indexed citations
12.
Abògúnr̀in, Ṣẹ̀yẹ, et al.. (2015). Budget impact analysis of botulinum toxin A therapy for upper limb spasticity in the United Kingdom. ClinicoEconomics and Outcomes Research. 7. 185–185. 10 indexed citations
13.
14.
Benedict, Ágnes, Robert A. Figlin, Per Sandström, et al.. (2011). Economic evaluation of new targeted therapies for the first‐line treatment of patients with metastatic renal cell carcinoma. British Journal of Urology. 108(5). 665–672. 37 indexed citations
15.
Remák, Edit, et al.. (2010). Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. EuroIntervention. 5(7). 826–832. 12 indexed citations
16.
Remák, Edit, et al.. (2007). PCN18 SUNITINIB VS. INTERFERON-ALPHA (IFN-ALPHA) IN FIRST-LINE METASTATIC RENAL CELL CARCINOMA (MRCC): AN ECONOMIC EVALUATION. Value in Health. 10(6). A327–A328. 1 indexed citations
17.
Remák, Edit, et al.. (2007). Economic evaluations of sunitinib versus interferon-alfa (IFN-α) in first-line metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 25(18_suppl). 6607–6607. 6 indexed citations
18.
Remák, Edit, et al.. (2007). 4514 POSTER Economic evaluation of sunitinib vs. interferon-alfa (IFN-a)in first-line metastatic renal cell carcinoma (mRCC). European Journal of Cancer Supplements. 5(4). 303–303. 2 indexed citations
19.
Selai, Caroline, Michael Trimble, Martin Price, & Edit Remák. (2005). Evaluation of health status in epilepsy using the EQ-5D questionnaire: a prospective, observational, 6-month study of adjunctive therapy with anti-epileptic drugs. Current Medical Research and Opinion. 21(5). 733–739. 25 indexed citations
20.
Remák, Edit & L. Brazil. (2004). Cost of managing women presenting with stage IV breast cancer in the United Kingdom. British Journal of Cancer. 91(1). 77–83. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisel Koepl Breakdown of academic impact, for papers by Per-Olof Thuresson Breakdown of academic impact, for papers by Anna Plym Breakdown of academic impact, for papers by Aviva G. Asnis-Alibozek Breakdown of academic impact, for papers by Timo Purmonen Breakdown of academic impact, for papers by S.M. Babineaux Breakdown of academic impact, for papers by K.R. Loughlin Breakdown of academic impact, for papers by Christine Langenaeken Breakdown of academic impact, for papers by V. Geyer Breakdown of academic impact, for papers by P. Stattin
Rankless by CCL
2026